上皮细胞粘附分子(EpCAM, CD326)是一种约40 kd的糖蛋白，最初被Koprowski及其同事在1979年描述为一种肿瘤相关抗原。由于其在多种癌症上的高水平表达，因此特别令人感兴趣。因此，EpCAM作为肿瘤诊断和治疗的候选蛋白就不足为奇了。大多数研究集中在EpCAM作为肿瘤治疗的一个良好靶点，涉及单克隆抗体和双/三特异性抗体，7种疫苗接种策略，8个毒素偶联抗体片段，9和一个抗体片段靶向sTRAIL融合蛋白与大多数其他CAMs在正常组织中的广泛表达模式相反，EpCAM的表达仅限于正常上皮细胞。基于EpCAM介导细胞-细胞粘附的观察，Litvinov及其同事11提出EpCAM是CAM。然而，最近的研究揭示了EpCAM更多功能的作用，不仅限于细胞粘附，而且类似于其他cam，包括信号传递、细胞迁移、增殖和分化等过程。
Anti Epithelial Cell Adhesion Molecule (EPCAM) mAb (Clone hrk29),CAC-HT-MAB1
Application: FC, IP, ELISA, WB
Clonality: Monoclonal
Host: Mouse
Purification: Purified – Affinity
Reactivity: Human
Epithelial cell adhesion molecule (EpCAM, CD326) is a glycoprotein of ∼40 kd that was initially described as a tumor-associated antigen by Koprowski and colleagues6 in 1979. It is of particular interest because of its high level of expression on a variety of carcinomas. Thus, it comes as no surprise that EpCAM is a candidate protein for tumor diagnosis and therapy. Most studies have focused on EpCAM as a favorable target for tumor therapy, involving monoclonal and bi-/tri-specific antibodies,7 vaccination strategies,8 toxin-conjugated antibody fragments,9 and an antibody fragment-targeted sTRAIL fusion protein.10 In contrast to the broad expression pattern of most other CAMs in normal tissues, the expression of EpCAM is restricted to normal epithelial cells. Based on the observation that EpCAM mediates cell-cell adhesion, Litvinov and colleagues11 proposed that EpCAM is a CAM. However, recent insights revealed a more versatile role for EpCAM, not merely limited to cell adhesion but similar to other CAMs, including processes such as signaling, cell migration, proliferation, and differentiation.